{"id":26008,"date":"2024-08-14T08:29:10","date_gmt":"2024-08-14T06:29:10","guid":{"rendered":"https:\/\/ggba.swiss\/geneva-biotech-relief-therapeutics-raises-up-to-usd-11-million-from-royalty-sales\/"},"modified":"2024-08-14T08:31:56","modified_gmt":"2024-08-14T06:31:56","slug":"la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/","title":{"rendered":"La biotech genevoise Relief Therapeutics l\u00e8ve jusqu&rsquo;\u00e0 USD 11 millions"},"content":{"rendered":"\n<p><a href=\"https:\/\/relieftherapeutics.com\/\">Relief Therapeutics<\/a>, une soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e \u00e0 Gen\u00e8ve et cot\u00e9e \u00e0 la SIX Swiss Exchange, a annonc\u00e9 la conclusion d&rsquo;un accord financier important avec <a href=\"https:\/\/www.swkhold.com\/\">SWK Funding LLC<\/a>, une filiale de SWK Holdings Corporation. Cet accord comprend la vente de royalties sur plusieurs produits de Relief, notamment OLPRUVA\u00ae, GOLIKE\u00ae et CAMBIA\u00ae, pour un montant total potentiel de USD 11 millions. Ces fonds seront utilis\u00e9s pour soutenir le d\u00e9veloppement clinique du traitement innovant de Relief pour l&rsquo;\u00e9pidermolyse bulleuse, RLF-TD011, et les autres avanc\u00e9es du pipeline.<\/p>\n\n\n\n<p>Selon les termes de l&rsquo;accord, Relief recevra un paiement initial en esp\u00e8ces de USD 5,75 millions, avec la possibilit\u00e9 d&rsquo;un paiement suppl\u00e9mentaire de USD 5,25 millions en fonction de la r\u00e9alisation de certaines \u00e9tapes \u00e0 court terme. Ces \u00e9tapes comprennent un paiement de USD 3,25 millions si les ventes nettes trimestrielles d&rsquo;OLPRUVA atteignent USD 1,5 million avant la fin du troisi\u00e8me trimestre 2025 et USD 2 millions si <a href=\"https:\/\/investors.zevra.com\/\">Zevra Therapeutics Inc.<\/a> re\u00e7oit l&rsquo;approbation de la FDA pour l&rsquo;arimoclomol, un traitement de la maladie de Niemann-Pick de type C (NPC), avant la fin de 2024.<\/p>\n\n\n\n<p>SWK a acquis l&rsquo;ensemble des royalties futures d&rsquo;<a href=\"https:\/\/olpruva.com\/\">OLPRUVA<\/a> issues de l&rsquo;accord pr\u00e9c\u00e9dent de licence avec Acer Therapeutics Inc., ainsi que l&rsquo;ensemble des royalties futures et des paiements d&rsquo;\u00e9tape issus de l&rsquo;accord de commercialisation de la famille de produits GOLIKE avec Eton Pharmaceuticals Inc. Malgr\u00e9 la vente, Relief conserve un important potentiel de croissance. SWK reversera \u00e0 Relief 80 % des redevances d&rsquo;OLPRUVA exc\u00e9dant USD 2,25 millions par an et toutes les royalties exc\u00e9dant USD 4,5 millions. Pour GOLIKE, SWK restituera 80 % des redevances d\u00e9passant USD 1,32 million par an et toutes les redevances d\u00e9passant USD 1,98 million. L&rsquo;accord prendra fin lorsque SWK aura re\u00e7u 2,75 fois son capital investi.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Relief Therapeutics a conclu un accord avec SWK Funding LLC pour obtenir jusqu&rsquo;\u00e0 USD 11 millions de financement non dilutif par le biais de la vente de royalties afin de soutenir son pipeline de d\u00e9veloppement clinique.<\/p>\n","protected":false},"author":6,"featured_media":26005,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1171],"class_list":["post-26008","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-pharma-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La biotech Relief Therapeutics l\u00e8ve jusqu&#039;\u00e0 USD 11 millions<\/title>\n<meta name=\"description\" content=\"Relief Therapeutics a conclu un accord avec SWK Funding en vue d&#039;obtenir un financement non dilutif d&#039;un montant maximal de USD 11 millions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La biotech Relief Therapeutics l\u00e8ve jusqu&#039;\u00e0 USD 11 millions\" \/>\n<meta property=\"og:description\" content=\"Relief Therapeutics a conclu un accord avec SWK Funding en vue d&#039;obtenir un financement non dilutif d&#039;un montant maximal de USD 11 millions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-14T06:29:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-14T06:31:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2360\" \/>\n\t<meta property=\"og:image:height\" content=\"1622\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"La biotech genevoise Relief Therapeutics l\u00e8ve jusqu&rsquo;\u00e0 USD 11 millions\",\"datePublished\":\"2024-08-14T06:29:10+00:00\",\"dateModified\":\"2024-08-14T06:31:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/\"},\"wordCount\":310,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/\",\"name\":\"La biotech Relief Therapeutics l\u00e8ve jusqu'\u00e0 USD 11 millions\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg\",\"datePublished\":\"2024-08-14T06:29:10+00:00\",\"dateModified\":\"2024-08-14T06:31:56+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Relief Therapeutics a conclu un accord avec SWK Funding en vue d'obtenir un financement non dilutif d'un montant maximal de USD 11 millions.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg\",\"width\":2360,\"height\":1622,\"caption\":\"Fond\u00e9e dans le but de r\u00e9pondre aux besoins non satisfaits dans le domaine des maladies rares, Relief Therapeutics continue de tirer parti de son portefeuille de produits commercialis\u00e9s et de ses plates-formes technologiques exclusives. | \u00a9 Relief Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La biotech genevoise Relief Therapeutics l\u00e8ve jusqu&#8217;\u00e0 USD 11 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La biotech Relief Therapeutics l\u00e8ve jusqu'\u00e0 USD 11 millions","description":"Relief Therapeutics a conclu un accord avec SWK Funding en vue d'obtenir un financement non dilutif d'un montant maximal de USD 11 millions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/","og_locale":"fr_FR","og_type":"article","og_title":"La biotech Relief Therapeutics l\u00e8ve jusqu'\u00e0 USD 11 millions","og_description":"Relief Therapeutics a conclu un accord avec SWK Funding en vue d'obtenir un financement non dilutif d'un montant maximal de USD 11 millions.","og_url":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-08-14T06:29:10+00:00","article_modified_time":"2024-08-14T06:31:56+00:00","og_image":[{"width":2360,"height":1622,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"La biotech genevoise Relief Therapeutics l\u00e8ve jusqu&rsquo;\u00e0 USD 11 millions","datePublished":"2024-08-14T06:29:10+00:00","dateModified":"2024-08-14T06:31:56+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/"},"wordCount":310,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg","keywords":["Biotech","Financing","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/","url":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/","name":"La biotech Relief Therapeutics l\u00e8ve jusqu'\u00e0 USD 11 millions","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg","datePublished":"2024-08-14T06:29:10+00:00","dateModified":"2024-08-14T06:31:56+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Relief Therapeutics a conclu un accord avec SWK Funding en vue d'obtenir un financement non dilutif d'un montant maximal de USD 11 millions.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/Relief-Therapeutics-1180x811-1.jpg","width":2360,"height":1622,"caption":"Fond\u00e9e dans le but de r\u00e9pondre aux besoins non satisfaits dans le domaine des maladies rares, Relief Therapeutics continue de tirer parti de son portefeuille de produits commercialis\u00e9s et de ses plates-formes technologiques exclusives. | \u00a9 Relief Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/la-biotech-genevoise-relief-therapeutics-leve-jusqua-usd-11-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"La biotech genevoise Relief Therapeutics l\u00e8ve jusqu&#8217;\u00e0 USD 11 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/26008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=26008"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/26008\/revisions"}],"predecessor-version":[{"id":26011,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/26008\/revisions\/26011"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/26005"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=26008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=26008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=26008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}